Herantis Pharma Plc, Press Release, 4 January 2023 at 09:00 A.M. EET
Herantis Pharma Plc (“Herantis”), developing disease modifying therapies for Parkinson’s disease, today announced that the management team will have meetings with potential investors and partners at:
Sachs 6th Annual Neuroscience Innovation Forum (Virtual)
Dates: January 16th-20th, 2023
Biotech Showcase (Virtual)
Dates: January 18th-19th, 2023
CEO, Antti Vuolanto will hold a virtual Company presentation:
Date: Tuesday, January 10, 2023
Time: 10:30AM (PST)
Track: Yosemite A (Ballroom Level)
If you want to learn more about Herantis and our asset HER-096, you can contact the conference organizers or connect with us at firstname.lastname@example.org.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.herantis.com.